Sortilin-Binding Small Molecules for Glucose Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Type 2 diabetes mellitus is characterized by insulin resistance and impaired glucose transport, largely due to mislocalization of Glut4 and decreased levels of sortilin, which are associated with obesity, and current therapies fail to effectively stabilize sortilin to enhance glucose uptake.
Innovation Solution
Development of small molecule compounds that bind to sortilin with high affinity, specifically targeting the VSP10 domain to stabilize the protein and promote glucose uptake by mediating its interaction with other protein molecules, thereby increasing glucose transport in adipocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat type 2 diabetes, then patients receive standard insulin-based treatment, but they fail to effectively stabilize sortilin to enhance glucose uptake
Solution Approach 1:
The patent introduces small molecule compounds as intermediary substances that bind to sortilin and stabilize it, thereby enhancing glucose uptake. These compounds act as mediators between the existing insulin therapy and the sortilin protein, improving the reliability of glucose transport without requiring changes to the overall therapeutic approach.
Solution Approach 2:
The invention changes the chemical parameter landscape by introducing small molecule ligands that bind to sortilin with specific affinity. This alters the stability parameter of sortilin, transforming it from an unstable, degraded state to a stabilized, functional state that can effectively mediate glucose uptake in diabetic conditions.
2Reliability
If sortilin levels are decreased in diabetic patients, then glucose transport is impaired, but increasing sortilin stability requires new compound development
Solution Approach 1:
The small molecule compounds are designed to self-bind to sortilin with high affinity, stabilizing the protein without requiring complex delivery systems or external activation. The compounds autonomously perform the stabilization function, simplifying the therapeutic mechanism while effectively addressing the decreased sortilin levels in diabetic patients.
Solution Approach 2:
The invention uses small molecule copies or analogs of natural sortilin ligands to achieve stabilization. By creating simplified molecular copies that retain the essential binding properties, the therapy can be developed and manufactured more easily compared to using complex biologics, while still achieving the desired glucose transport improvement.
3Stability of the object's composition
If small molecule compounds bind to the VSP10 domain of sortilin, then sortilin stability increases, but specific binding affinity requirements must be met
Solution Approach 1:
The small molecule compounds are designed to bind specifically to the VSP10 domain of sortilin, concentrating their stabilizing effect at this critical local region. This localized binding approach ensures high stability improvement at the target site while maintaining selectivity, allowing the compounds to meet stringent binding affinity requirements without affecting other parts of the protein unnecessarily.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The identified compounds significantly increase glucose uptake in adipocytes by stabilizing sortilin, as demonstrated by increased expression levels and enhanced insulin-induced glucose transport, offering a potential therapeutic approach for correcting defects in glucose transport and addressing obesity in diabetic patients.
Implementation Method 1
small molecule compounds that bind to sortilin with high affinity, specifically targeting the VSP10 domain to stabilize the protein
Implementation Method 2
promote glucose uptake by mediating its interaction with other protein molecules, thereby increasing glucose transport in adipocytes
Implementation Method 3
translocation of fat and muscle specific transporter-Glut4 to the plasma membrane
Data Source
AI summary
Various scaffolds of small molecules capable of binding to the active site of sortilin are identified by in silico methods. These scaffolds include norbornene anhydride amino acid adducts and 2-substituted 3-oxo-1,2,3,4-tetrahydro-2-quinoxalines. These sortilin ligands increase the uptake of glucose in 3T3L1 cells and can be employed in compositions to increase uptake of glucose for the treatment of diabetic patents.